EGAPP|Evaluation of Genomic Applications in Practice and Prevention|Home

The EGAPP Working Group was established in 2005 to support the development of a systematic process for assessing the available evidence regarding the validity and utility of rapidly emerging genetic tests for clinical practice. This independent, multidisciplinary panel prioritizes and selects tests, reviews CDC-commissioned evidence reports and other contextual factors, highlights critical knowledge gaps, and provides guidance on appropriate use of genetic tests in specific clinical scenarios.

What's New
The next EWG meeting will be held on January 30 and 31, 2012. The EWG announces the selection of 4 new EGAPP Working Group Members: Jonathan Berg, A. Cecile Janssens, Marc S. Williams, and Doris T. Zallen. more

EGAPP Recommendations

Cardiovascular Health: Outcomes of Genetic Testing in Adults with a History of Venous Thromboembolism
Breast Cancer: Can tumor gene expression profiling improve outcomes…
Cardiovascular Health: Genomic profiling to assess cardiovascular risk to improve cardiovascular health…
Colorectal Cancer (Lynch syndrome): Genetic testing strategies in newly diagnosed individuals…
Colorectal Cancer: Can UGT1A1 genotyping reduce morbidity and mortality…
Depression: Testing for cytochrome P450 polymorphisms in adults…

Links to organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by EGAPP, and none should be inferred. EGAPP is not responsible for the content of the individual organization Web pages found at these links.

Page last updated: January 27, 2012
Page last reviewed: May 26, 2009
Content Source: EGAPP Team

What's New

EGAPP Recommendations